Benjamin G Vincent
Overview
Explore the profile of Benjamin G Vincent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
7623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Asad S, Kananen K, Mueller K, Fraser Symmans W, Wen Y, Perou C, et al.
JCO Clin Cancer Inform
. 2022 Apr;
6:e2100193.
PMID: 35404674
No abstract available.
22.
Karasarides M, Cogdill A, Robbins P, Bowden M, Burton E, Butterfield L, et al.
Cancer Immunol Res
. 2022 Apr;
10(4):372-383.
PMID: 35362046
Immune-checkpoint inhibitors (ICI), although revolutionary in improving long-term survival outcomes, are mostly effective in patients with immune-responsive tumors. Most patients with cancer either do not respond to ICIs at all...
23.
Innocenti F, Yazdani A, Rashid N, Qu X, Ou F, Van Buren S, et al.
Clin Cancer Res
. 2022 Feb;
28(8):1690-1700.
PMID: 35176136
Purpose: CALGB/SWOG 80405 was a randomized phase III trial in first-line patients with metastatic colorectal cancer treated with bevacizumab, cetuximab, or both, plus chemotherapy. We tested the effect of tumor...
24.
Nishijima T, Kardos J, Chai S, Smith C, Bortone D, Selitsky S, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-10.
PMID: 35172495
Purpose: Claudin-low molecular subtypes have been identified in breast and bladder cancers and are characterized by low expression of claudins, enrichment for epithelial-to-mesenchymal transition (EMT), and tumor-initiating cell (TIC) features....
25.
Anders C, Woodcock M, Van Swearingen A, Moore D, Sambade M, Laurie S, et al.
J Immunother Cancer
. 2022 Feb;
10(2).
PMID: 35121644
Purpose: Triple negative breast cancer (TNBC) is characterized by the presence of immune cells in the tumor microenvironment, however, the response to single-agent immune checkpoint inhibitor (ICI) therapy is modest....
26.
Downs-Canner S, Meier J, Vincent B, Serody J
Annu Rev Immunol
. 2022 Jan;
40:169-193.
PMID: 35044794
The tumor microenvironment (TME) is a heterogeneous, complex organization composed of tumor, stroma, and endothelial cells that is characterized by cross talk between tumor and innate and adaptive immune cells....
27.
Vincent B, Szustakowski J, Doshi P, Mason M, Guinney J, Carbone D
JCO Precis Oncol
. 2022 Jan;
5:51-54.
PMID: 34994587
No abstract available.
28.
Tsai Y, Woodcock M, Azam S, Thorne L, Kanchi K, Parker J, et al.
J Clin Invest
. 2022 Jan;
132(4).
PMID: 34990404
BACKGROUNDThe KRAS proto-oncogene is among the most frequently mutated genes in cancer, yet for 40 years it remained an elusive therapeutic target. Recently, allosteric inhibitors that covalently bind to KRAS...
29.
Zeidner J, Vincent B, Ivanova A, Moore D, McKinnon K, Wilkinson A, et al.
Blood Cancer Discov
. 2021 Nov;
2(6):616-629.
PMID: 34778801
Significance: Immune-checkpoint blockade with pembrolizumab was tolerable and feasible after high-dose cytarabine in R/R AML, with encouraging clinical activity, particularly in refractory AML and those receiving treatment as first salvage...
30.
Tschernia N, Kumar V, Moore D, Vincent B, Coombs C, van Deventer H, et al.
Transplant Cell Ther
. 2021 Sep;
27(12):1021.e1-1021.e5.
PMID: 34474164
Programmed death 1 (PD-1) is an integral component of acute myelogenous leukemia (AML) immune evasion, chemotherapy resistance, and disease progression. PD-1 inhibitors are being investigated as treatment for AML in...